ATE298003T1 - Ein tumorsuppressor namens ts10q23.3 - Google Patents

Ein tumorsuppressor namens ts10q23.3

Info

Publication number
ATE298003T1
ATE298003T1 AT98943394T AT98943394T ATE298003T1 AT E298003 T1 ATE298003 T1 AT E298003T1 AT 98943394 T AT98943394 T AT 98943394T AT 98943394 T AT98943394 T AT 98943394T AT E298003 T1 ATE298003 T1 AT E298003T1
Authority
AT
Austria
Prior art keywords
gene
tumor suppressor
region
demonstrated
protein
Prior art date
Application number
AT98943394T
Other languages
English (en)
Inventor
Peter Steck
Mark A Pershouse
Samar A Jasser
W K Alfred Yung
Sean V Tavtigian
Original Assignee
Univ Texas
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Myriad Genetics Inc filed Critical Univ Texas
Application granted granted Critical
Publication of ATE298003T1 publication Critical patent/ATE298003T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98943394T 1997-08-26 1998-08-26 Ein tumorsuppressor namens ts10q23.3 ATE298003T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5775097P 1997-08-26 1997-08-26
US8356398P 1998-04-30 1998-04-30
PCT/US1998/017636 WO1999010537A1 (en) 1997-08-26 1998-08-26 A tumor suppressor designated ts10q23.3

Publications (1)

Publication Number Publication Date
ATE298003T1 true ATE298003T1 (de) 2005-07-15

Family

ID=26736860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98943394T ATE298003T1 (de) 1997-08-26 1998-08-26 Ein tumorsuppressor namens ts10q23.3

Country Status (8)

Country Link
EP (1) EP1012338B1 (de)
JP (3) JP4339506B2 (de)
AT (1) ATE298003T1 (de)
AU (1) AU9120398A (de)
CA (1) CA2301199C (de)
DE (1) DE69830596T2 (de)
ES (1) ES2245039T3 (de)
WO (1) WO1999010537A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
US6262242B1 (en) * 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US6284538B1 (en) * 1999-07-21 2001-09-04 Isis Pharmaceuticals, Inc. Antisense inhibition of PTEN expression
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
US7041445B2 (en) * 1999-11-15 2006-05-09 Clontech Laboratories, Inc. Long oligonucleotide arrays
US20020025521A1 (en) 1999-11-29 2002-02-28 Lu Kun Ping Pin1 as a marker for abnormal cell growth
AU2001265137B2 (en) * 2000-05-30 2007-06-14 Indiana University Research And Technology Corporation Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
JP2002142765A (ja) * 2000-07-14 2002-05-21 Tosoh Corp 新規ゲノム解析法
JP6472075B2 (ja) * 2015-02-26 2019-02-20 学校法人順天堂 Gistの予後又は治療抵抗性の診断

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262242B1 (en) * 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3

Also Published As

Publication number Publication date
WO1999010537A1 (en) 1999-03-04
EP1012338A4 (de) 2002-11-20
DE69830596T2 (de) 2006-03-16
EP1012338A1 (de) 2000-06-28
ES2245039T3 (es) 2005-12-16
EP1012338B1 (de) 2005-06-15
JP4339506B2 (ja) 2009-10-07
JP2008263988A (ja) 2008-11-06
DE69830596D1 (de) 2005-07-21
AU9120398A (en) 1999-03-16
CA2301199A1 (en) 1999-03-04
JP2001514015A (ja) 2001-09-11
JP4454670B2 (ja) 2010-04-21
JP2010051330A (ja) 2010-03-11
CA2301199C (en) 2013-02-05

Similar Documents

Publication Publication Date Title
EP2366712A3 (de) TS10Q23.3 Tumorunterdrückung
Wang et al. The covalent and three-dimensional structural of concanavalin AI Amino acid sequence of cyanogen bromide fragments F1 and F2.
TR200200937T2 (tr) Yumurtalık kanseri tedavisi için bileşimler.
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
ATE458050T1 (de) Promotion oder inhibition von angiogenese und kardiovaskularisation
ATE259648T1 (de) Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
TR200101482T2 (tr) WT1'e özgü imünoterapi için bileşimler
DE69940964D1 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
TR200003087T2 (tr) Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
HUT65373A (en) Analytical tracers for cancer, particularly malignant breast cancer
TR200003515T2 (tr) İkame edilmiş indolinon, bunların imalatı ve ilaç olarak kullanımı
DE69830596D1 (de) Ein tumorsuppressor namens ts10q23.3
DK21985A (da) Monoklonale antistoffer mod ikke-smaacellet lungecancer
ATE175996T1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
Goldenring et al. Isolation of brain Ca2+-calmodulin tubulin kinase containing calmodulin binding proteins
EA200100276A1 (ru) Рецептор цитокина zalpha11
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
DE69021742D1 (de) Verfahren zum Nachweis von kleinzelligem Carzinom und die Verwendung von Sequenzen, die Acylpeptid-Hydrolase codieren, für diesen zweck.
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
WO2000050595A3 (en) Nucleic acid molecules associated with melanoma and thyroid tumors
EP0815240A4 (de) Neue menschliche proteine, die cyclinebhängigen kinasen ähneln, sowie methoden zu deren verwendung
BR0312483A (pt) Anticorpos e seus usos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties